Entrada Therapeutics, Inc. Common Stock (TRDA)
PHARMACEUTICAL PREPARATIONS
Entrada Therapeutics, Inc. Common Stock (TRDA) is listed on Nasdaq, where it has traded since October 29, 2021.
- Listed On
- Nasdaq
- Listed Since
- October 29, 2021
- Employees
- 152
- Market Cap
- $240M
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 125 institutions reported holding TRDA, with 29.1 million shares worth $214.4 million in aggregate. The largest reported holder was Baker Bros. Advisors, with 5.1 million shares worth $37.3 million. Of the 5 largest holders listed below, 1 opened a new position in TRDA, 2 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Baker Bros. Advisors | 5,072,730 | $37M | Unchanged |
| 5am Venture Management | 4,056,379 | $30M | Unchanged |
| BlackRock | 2,583,333 | $19M | Added 9.52% |
| Merck & Co | 1,739,768 | $13M | New position |
| Vanguard | 1,700,222 | $13M | Added 2.93% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TRDA?
Entrada Therapeutics, Inc. Common Stock (TRDA) is listed on Nasdaq, where it has traded since October 29, 2021.
Who are the largest institutional holders of TRDA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TRDA were Baker Bros. Advisors, 5am Venture Management and BlackRock.
How many institutions own TRDA?
125 institutions reported a position in TRDA for the quarter ended June 30, 2026, worth $214.4 million in total.
Did institutions buy or sell TRDA last quarter?
Of the 5 largest reported holders, 1 opened a new position in TRDA, 2 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TRDA.
Every reported institutional holder, plus insider and congressional trades in TRDA, on SentiSense.